Reported Toxicities Associated with Stereotactic Body Radiation Therapy

  • Simon S. Lo
  • Arjun Sahgal
  • Charles A. Kunos
  • Bin S. Teh
  • Min Yao
  • Mitchell Machtay
  • Nina A. Mayr
  • Zhibin Huang
  • Eric L. Chang
Part of the Medical Radiology book series (MEDRAD)


Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) entails the delivery of ablative doses of radiation to extracranial targets. With the increase in the use of SBRT to treat extracranial tumors of various sites, more clinical experience has been gained. Despite the sharp falloff of the radiation dose beyond the prescribed isodose line, which is a characteristic of SBRT, various serious treatment-related complications have been observed, especially when the target volume is very close to organs-at-risk (OARs). Knowledge of potential complications caused by radiation in the ablative dose range will enhance understanding of tolerance of various OARs and this will facilitate further development of safer SBRT regimens for different body sites. This chapter will provide an overview of the severe toxicities associated with SBRT.


Brachial Plexus Intensity Modulate Radiation Therapy Stereotactic Body Radiation Therapy Spinal Metastasis Radiation Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Andolino DL, Forquer JA, Henderson MA, Barriger RB, Shapiro RH, Brabham JG, Johnstone PA, Cardenes HR, Fakiris AJ (2011a) Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver. Int J Radiat Oncol Biol Phys 80(3):692–697. S0360-3016(10)00455-4[pii], doi: 10.1016/j.ijrobp.2010.03.020
  2. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR (2011b) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81(4):e447–e453. S0360-3016(11)00527-X[pii], doi: 10.1016/j.ijrobp.2011.04.011 Google Scholar
  3. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ (2010) A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. S0360-3016(10)03263-3[pii], doi:  10.1016/j.ijrobp.2010.08.056
  4. Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JS, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R (2008) Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer—a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol 88(3):359–367. S0167-8140(08)00384-8[pii], doi: 10.1016/j.radonc.2008.07.019
  5. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27:3290–3296PubMedCrossRefGoogle Scholar
  6. Bishawi M, Kim B, Moore WH, Bilfinger TV (2011) Pulmonary function testing after stereotactic body radiotherapy to the lung. Int J Radiat Oncol Biol Phys. S0360-3016(11)00204-5[pii], doi:  10.1016/j.ijrobp.2011.01.037
  7. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R (2011) Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29(15):2020–2026. JCO.2010.31.4377[pii], doi: 10.1200/JCO.2010.31.4377 Google Scholar
  8. Bongers EM, Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S (2011) Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer. J Thorac Oncol. doi:  10.1097/JTO.0b013e3182307e74
  9. Cardenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12(3):218–225PubMedCrossRefGoogle Scholar
  10. Cengiz M, Ozyigit G, Yazici G, Dogan A, Yildiz F, Zorlu F, Gurkaynak M, Gullu IH, Hosal S, Akyol F (2011) Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys 81(1):104–109. S0360-3016(10)00603-6[pii], doi: 10.1016/j.ijrobp.2010.04.027 Google Scholar
  11. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R (2008) Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967–971PubMedCrossRefGoogle Scholar
  12. Chua DT, Sham JS, Hung KN, Leung LH, Cheng PW, Kwong PW (2001) Salvage treatment for persistent and recurrent T1–2 nasopharyngeal carcinoma by stereotactic radiosurgery. Head Neck 23(9):791–798. 10.1002/hed.1113[pii]Google Scholar
  13. Chua DT, Sham JS, Kwong PW, Hung KN, Leung LH (2003) Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 56(1):177–183. S0360301603000749[pii]Google Scholar
  14. Chua DT, Wu SX, Lee V, Tsang J (2009) Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis. Head Neck Oncol 1:13. 1758-3284-1-13[pii], doi: 10.1186/1758-3284-1-13
  15. Dodd RL, Ryu MR, Kamnerdsupaphon P, Gibbs IC, Chang SD Jr, Adler JR Jr (2006) CyberKnife radiosurgery for benign intradural extramedullary spinal tumors. Neurosurgery 58(4): 674–685 (discussion pp 674–685)Google Scholar
  16. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM (2010) Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76(3):796–801PubMedCrossRefGoogle Scholar
  17. Forquer JA, Fakiris AJ, Timmerman RD, Lo SS, Perkins SM, McGarry RC, Johnstone PA (2009) Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 93:408–413PubMedCrossRefGoogle Scholar
  18. Garg AK, Wang XS, Shiu AS, Allen P, Yang J, McAleer MF, Azeem S, Rhines LD, Chang EL (2011) Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer 117(15):3509–3516. doi: 10.1002/cncr.25918 PubMedCrossRefGoogle Scholar
  19. Gerszten PC, Burton SA, Ozhasoglu C, McCue KJ, Quinn AE (2008) Radiosurgery for benign intradural spinal tumors. Neurosurgery 62(4): 887–895 (discussion pp 895–886)Google Scholar
  20. Gibbs IC, Kamnerdsupaphon P, Ryu MR, Dodd R, Kiernan M, Chang SD, Adler JR Jr (2007) Image-guided robotic radiosurgery for spinal metastases. Radiother Oncol 82(2):185–190PubMedCrossRefGoogle Scholar
  21. Gibbs IC, Patil C, Gerszten PC, Adler JR Jr, Burton SA (2009) Delayed radiation-induced myelopathy after spinal radiosurgery. Neurosurgery 64(2Suppl):A67–A72. 00006123-200902001-00011[pii], doi: 10.1227/01.NEU.0000341628.98141.B6 Google Scholar
  22. Gomez DR, Hunt MA, Jackson A, O’Meara WP, Bukanova EN, Zelefsky MJ, Yamada Y, Rosenzweig KE (2009) Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy. Radiother Oncol 93(3):414–418. S0167-8140(09)00611-2[pii], doi: 10.1016/j.radonc.2009.10.017
  23. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28(6):928–935. JCO.2009.25.0928[pii], doi: 10.1200/JCO.2009.25.0928 Google Scholar
  24. Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, Richter A, Wilbert J, Flentje M (2010) Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol94(1):53–59. S0167-8140(09)00662-8[pii], doi: 10.1016/j.radonc.2009.12.004
  25. Hara R, Itami J, Komiyama T, Katoh D, Kondo T (2004) Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125(1):340–344PubMedCrossRefGoogle Scholar
  26. Henderson M, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M, Timmerman R (2008) Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(2):404–409. S0360-3016(08)00045-X[pii], doi: 10.1016/j.ijrobp.2007.12.051
  27. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19(1):164–170PubMedGoogle Scholar
  28. Herfarth KK, Hof H, Bahner ML, Lohr F, Hoss A, van Kaick G, Wannenmacher M, Debus J (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57(2):444–451. S0360301603005868[pii]Google Scholar
  29. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL (2011) Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol 34(2):165–172. doi: 10.1097/COC.0b013e3181dbb73e PubMedGoogle Scholar
  30. Hoppe BS, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke ED, Lovelock DM, Hunt MA, Rosenzweig KE (2008) Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who’s at risk? Int J Radiat Oncol Biol Phys 72(5):1283–1286PubMedCrossRefGoogle Scholar
  31. Housman DM, Solomon S, Maybody M, Thornton RH, Zatcky JM, Lovelock M, Mechalakos JG, Yamada Y (2011) Temporary organ displacement for stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(2): S30Google Scholar
  32. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, Nellemann H, Kiil Berthelsen A, Eberholst F, Engelholm SA, von der Maase H (2005) Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 76(1):48–53PubMedCrossRefGoogle Scholar
  33. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen A, Grau C, Aage Engelholm S, Von der Maase H (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830PubMedCrossRefGoogle Scholar
  34. Ishiyama H, Teh BS, Lo SS, Mathews T, Blanco A, Amato R, Ellis RJ, Mayr NA, Paulino AC, Xu B, Butler BE (2011) Stereotactic body radiation therapy for prostate cancer. Future Oncol 7(9):1077–1086. doi: 10.2217/fon.11.86 PubMedCrossRefGoogle Scholar
  35. Joyner M, Salter BJ, Papanikolaou N, Fuss M (2006) Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol 45(7):802–807. LK25X1R353386184[pii], doi: 10.1080/02841860600915322 Google Scholar
  36. Kodani N, Yamazaki H, Tsubokura T, Shiomi H, Kobayashi K, Nishimura T, Aibe N, Ikeno H (2011) Stereotactic body radiation therapy for head and neck tumor: disease control and morbidity outcomes. J Radiat Res (Tokyo) 52(1):24–31. JST.JSTAGE/jrr/10086[pii]Google Scholar
  37. Kunos C, von Gruenigen V, Waggoner S, Brindle J, Zhang Y, Myers B, Funkhouser G, Wessels B, Einstein D (2008) Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. Technol Cancer Res Treat7 (5):375–380. d=3032&c=4269&p=16829&do=detail[pii]Google Scholar
  38. Kunos C, Chen W, DeBernardo R, Waggoner S, Brindle J, Zhang Y, Williams J, Einstein D (2009) Stereotactic body radiosurgery for pelvic relapse of gynecologic malignancies. Technol Cancer Res Treat 8(5):393–400. d=3036&c=4295&p=17751&do=detail[pii]Google Scholar
  39. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591PubMedCrossRefGoogle Scholar
  40. Lo SS, Fakiris AJ, Papiez L, Abdulrahman R, McGarry RC, Henderson MA, Forquer JA, Hoopes D, Timmerman RD (2008) Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Rev Anticancer Ther 8(1):87–98. doi: 10.1586/14737140.8.1.87 PubMedCrossRefGoogle Scholar
  41. Lo SS, Fakiris AJ, Wang JZ, Mayr NA (2009a) In regard to Hoppe et al. (Int J Radiat Oncol Biol Phys 2008;72:1283–1286). Int J Radiat Oncol Biol Phys 74(3):977; author reply978. S0360-3016(09)00343-5[pii], doi: 10.1016/j.ijrobp.2009.02.046
  42. Lo SS, Fakiris AJ, Teh BS, Cardenes HR, Henderson MA, Forquer JA, Papiez L, McGarry RC, Wang JZ, Li K, Mayr NA, Timmerman RD (2009b) Stereotactic body radiation therapy for oligometastases. Expert Rev Anticancer Ther 9(5):621–635PubMedCrossRefGoogle Scholar
  43. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, Teh BS, McGarry RC, Cardenes HR, Timmerman RD (2010a) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7(1):44–54PubMedCrossRefGoogle Scholar
  44. Lo SS, Sahgal A, Wang JZ, Mayr NA, Sloan A, Mendel E, Chang EL (2010b) Stereotactic body radiation therapy for spinal metastases. Discov Med 9(47):289–296PubMedGoogle Scholar
  45. Lo SS, Dawson LA, Kim EY, Mayr NA, Wang JZ, Huang Z, Cardenes HR (2010c) Stereotactic body radiation therapy for hepatocellular carcinoma. Discov Med 9(48):404–410PubMedGoogle Scholar
  46. Mahadevan A, Floyd S, Wong E, Jeyapalan S, Groff M, Kasper E (2010) Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. Int J Radiat Oncol Biol Phys. S0360-3016(10)03058-0[pii], doi: 10.1016/j.ijrobp.2010.08.012
  47. Mayr NA, Huang Z, Sohn JW, Lo SS, Teh BS, Lu JJ, Grecula JC, Kunos C (2011) Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert Rev Anticancer Ther 11(7):1069–1075. doi: 10.1586/era.11.81 PubMedCrossRefGoogle Scholar
  48. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD (2005) Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 63(4):1010–1015PubMedCrossRefGoogle Scholar
  49. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JN, Levendag PC (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45(7):831–837PubMedCrossRefGoogle Scholar
  50. Mitsuhashi N, Sakurai H, Katano S, Kurosaki H, Hasegawa M, Akimoto T, Nozaki M, Hayakawa K, Niibe H (1999) Stereotactic radiotherapy for locally recurrent nasopharyngeal carcinoma. Laryngoscope 109(5):805–809PubMedCrossRefGoogle Scholar
  51. Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC (2010) A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 78(5):1420–1426. S0360-3016(09)03522-6[pii], doi: 10.1016/j.ijrobp.2009.09.075 Google Scholar
  52. Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE (2011) Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys. S0360-3016(11)00519-0[pii], doi:  10.1016/j.ijrobp.2011.03.053
  53. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63(5):1427–1431PubMedCrossRefGoogle Scholar
  54. Pai PC, Chuang CC, Wei KC, Tsang NM, Tseng CK, Chang CN (2002) Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 24(8):748–753. doi: 10.1002/hed.10116 PubMedCrossRefGoogle Scholar
  55. Pettersson N, Nyman J, Johansson KA (2009) Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 91(3):360–368PubMedCrossRefGoogle Scholar
  56. Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, Mantovani C, Borasio P, Scagliotti GV, Ragona R (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. LungCancer68(1):72–77. S0169-5002(09)00310-9[pii], doi: 10.1016/j.lungcan.2009.05.007
  57. Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, Lis E (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27(30):5075–5079. JCO.2008.19.3508[pii], doi: 10.1200/JCO.2008.19.3508 Google Scholar
  58. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578PubMedCrossRefGoogle Scholar
  59. Ryu S, Jin JY, Jin R, Rock J, Ajlouni M, Movsas B, Rosenblum M, Kim JH (2007) Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer 109(3):628–636PubMedCrossRefGoogle Scholar
  60. Sahgal A, Larson DA, Chang EL (2008) Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71(3):652–665. S0360-3016(08)00405-7[pii], doi: 10.1016/j.ijrobp.2008.02.060 Google Scholar
  61. Sahgal A, Ames C, Chou D, Ma L, Huang K, Xu W, Chin C, Weinberg V, Chuang C, Weinstein P, Larson DA (2009) Stereotactic body radiotherapy is effective salvage therapy for patients with prior radiation of spinal metastases. Int J Radiat Oncol Biol Phys 74(3):723–731. S0360-3016(08)03500-1[pii], doi: 10.1016/j.ijrobp.2008.09.020
  62. Sahgal A, Ma L, Weinberg V, Gibbs IC, Chao S, Chang UK, Werner-Wasik M, Angelov L, Chang EL, Sohn MJ, Soltys SG, Letourneau D, Ryu S, Gerszten PC, Fowler J, Wong CS, Larson DA (2012) Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 82(1)107–116 S0360-3016(10)03067-1[pii], doi:  10.1016/j.ijrobp.2010.08.021
  63. Sahgal A, Ma L, Gibbs I, Gerszten PC, Ryu S, Soltys S, Weinberg V, Wong S, Chang E, Fowler J, Larson DA (2010) Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 77(2):548–553. S0360-3016(09)00772-X[pii], doi: 10.1016/j.ijrobp.2009.05.023 Google Scholar
  64. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678–686PubMedCrossRefGoogle Scholar
  65. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, Movsas B, Ryu S (2009) Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 74(4):1047–1053. S0360-3016(08)03498-6[pii], doi: 10.1016/j.ijrobp.2008.09.022 Google Scholar
  66. Siddiqui F, Raben D, Lu JJ, Grecula JC, Lo SS, Huang Z, Mayr NA, Teh BS, Yao M (2011) Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther 11(9):1429–1436. doi: 10.1586/era.11.110 PubMedCrossRefGoogle Scholar
  67. Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, Je HU, Park CI, Lee JS, Choi EK (2009) Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 66(1):89–93. S0169-5002(08)00678-8[pii], doi: 10.1016/j.lungcan.2008.12.016 Google Scholar
  68. Stephans KL, Djemil T, Reddy CA, Gajdos SM, Kolar M, Machuzak M, Mazzone P, Videtic GM (2009) Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 4(7):838–844. doi: 10.1097/JTO.0b013e3181a99ff6 PubMedCrossRefGoogle Scholar
  69. Stephans KL, Djemil T, Tendulkar RD, Robinson CG, Reddy CA, Videtic GM (2011) Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys. S0360-3016(10)03634-5[pii], doi: 10.1016/j.ijrobp.2010.12.002
  70. Takeda A, Ohashi T, Kunieda E, Enomoto T, Sanuki N, Takeda T, Shigematsu N (2010) Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors. Int J Radiat Oncol BiolPhys77(3):685–690. S0360-3016(09)00836-0[pii], doi: 10.1016/j.ijrobp.2009.06.001
  71. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839. 24/30/4833[pii], doi: 10.1200/JCO.2006.07.5937 Google Scholar
  72. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA303(11):1070–1076. 303/11/1070[pii], doi: 10.1001/jama.2010.261
  73. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26(4):657–664PubMedCrossRefGoogle Scholar
  74. Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ, Hwang J, Slack RS, Noone AM, Harter KW (2010) Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys77(5):1411–1419. S0360-3016(09)02779-5[pii], doi: 10.1016/j.ijrobp.2009.06.070 Google Scholar
  75. Voroney JP, Hope A, Dahele MR, Purdie TG, Franks KN, Pearson S, Cho JB, Sun A, Payne DG, Bissonnette JP, Bezjak A, Brade AM (2009) Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 4(8):1035–1037. 01243894-200908000-00019[pii], doi: 10.1097/JTO.0b013e3181ae2962 Google Scholar
  76. Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R, Chang JY (2011) Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 81(1):91–96. S0360-3016(10)00598-5[pii], doi: 10.1016/j.ijrobp.2010.04.022
  77. Wu SX, Chua DT, Deng ML, Zhao C, Li FY, Sham JS, Wang HY, Bao Y, Gao YH, Zeng ZF (2007) Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 69(3):761–769. S0360-3016(07)00556-1[pii], doi: 10.1016/j.ijrobp.2007.03.037 Google Scholar
  78. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, Flentje M (2006) Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 45(7):838–847PubMedCrossRefGoogle Scholar
  79. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71(2):484–490PubMedCrossRefGoogle Scholar
  80. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, Shiraishi K, Sasano N, Ohtomo K (2007) Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2:21. 1748-717X-2-21[pii], doi: 10.1186/1748-717X-2-21 Google Scholar
  81. Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K, Nakagawa K (2010) Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 5:32. 1748-717X-5-32[pii], doi: 10.1186/1748-717X-5-32

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Simon S. Lo
    • 1
  • Arjun Sahgal
    • 2
  • Charles A. Kunos
    • 1
  • Bin S. Teh
    • 3
  • Min Yao
    • 1
  • Mitchell Machtay
    • 1
  • Nina A. Mayr
    • 5
  • Zhibin Huang
    • 6
  • Eric L. Chang
    • 4
  1. 1.Department of Radiation OncologyUniversity Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve UniversityClevelandUSA
  2. 2.Department of Radiation Oncology, Princess Margaret Hospital and Toronto Sunnybrook HospitalUniversity of TorontoTorontoCanada
  3. 3.Department of Radiation Oncology, Weill Cornell College of MedicineThe Methodist Hospital Cancer Center and Research InstituteHoustonUSA
  4. 4.Department of Radiation Oncology, Keck School of Medicine and Norris Cancer HospitalUniversity of Southern CaliforniaLos AngelesUSA
  5. 5.Department of Radiation Oncology, Arthur G. James Cancer HospitalThe Ohio State UniversityColumbusUSA
  6. 6.Department of Radiation OncologyEast Carolina UniversityGreenvilleUSA

Personalised recommendations